Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3 episode artwork

EPISODE · Jun 11, 2026 · 9 MIN

Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis data. AstraZeneca's oral GLP-1 elecoglipron hits 11.8% weight loss.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Parabilis Medicines, biotech IPO, zolucatetide, TG Therapeutics, Briumvi, ublituximab, myasthenia gravis, Sanofi, riliprubart, CIDP, complement inhibitor, AstraZeneca, elecoglipron, GLP-1, oral obesity, Novartis, Orionis Biosciences, molecular glue, Beren Therapeutics, adrabetadex, Niemann-Pick disease, SonoThera, Ethyreal, City Therapeutics, Shattuck Labs, Treeline Biosciences, COINS Act, Pfizer, Lilly, Moderna

Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis data. AstraZeneca's oral GLP-1 elecoglipron hits 11.8% weight loss.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Parabilis Medicines, biotech IPO, zolucatetide, TG Therapeutics, Briumvi, ublituximab, myasthenia gravis, Sanofi, riliprubart, CIDP, complement inhibitor, AstraZeneca, elecoglipron, GLP-1, oral obesity, Novartis, Orionis Biosciences, molecular glue, Beren Therapeutics, adrabetadex, Niemann-Pick disease, SonoThera, Ethyreal, City Therapeutics, Shattuck Labs, Treeline Biosciences, COINS Act, Pfizer, Lilly, Moderna

NOW PLAYING

Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

0:00 9:44

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 9 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on June 11, 2026.

What is this episode about?

Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis data. AstraZeneca's oral...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!